The overlapping targets among the remaining 4 drugs included the following: i) discoidin domain receptor 1 (DDR1) protein, a receptor tyrosine kinase involved in cell–cell and cell–matrix adhesion and upregulated in several cancers (DDR1 was identified as a common target among all 4 drugs, namely, bafetinib, ponatinib, DDR1 7rh, and VU6015929); ii) Src kinases (Lyn/Src); iii) breakpoint cluster region (BCR) protein, an activator of GEF (Guanosine nucleotide exchange factor), involved in oncogenic transformations; and iv) ABL1 kinase, involved in growth, survival, and cytoskeletal remodeling. The gene discussed is NTRK1; the disease is cancer.